The Antimonopoly Committee of Ukraine is considering a concentration case on the acquisition of a part of Allergan Plc (Dublin, Ireland) by Teva Pharmaceutical Industries Ltd. (Petah-Tikva, Israel) and the committee is conducting a poll how the deal could influence the Ukrainian pharmaceutical market, the press service of the committee has reported.

The press service said that the regulator asks the public to present the grounded opinion on the possible influence of the deal.

The poll is conducted on the website of the regulator.

As reported, in July 2015, Teva decided not to acquire a rival - Mylan N.V. (the U.S.) and announced its plans to acquire Allergan Plc that products generics. Teva will pay $40.5 billion for Allergan Generics, including $33.75 billion in cash. Thus, the Israeli firm plans to strengthen its leading position on the generics market.

In turn, in late November 2015, Ireland's Allergan Plc and U.S. Pfizer Inc officially announced a merger worth $160 billion, and the largest pharmaceutical and biotechnological company in the world would be created.

In November 2014, Actavis Plc (the U.S.), a large generics producer, acquired U.S. Allergan that particularly produces Botox for $66 billion or $219 per share. In March 2015 Actavis finalized the deal, forming a new pharmaceutical company worth over $23 billion.